Objectives:Currently,there exist two approaches to the treatment of malignant neoplasms:the Karanahan technology and in situ vaccination,which are based on chronometric delivery of therapeutic agents to the tumor depe...Objectives:Currently,there exist two approaches to the treatment of malignant neoplasms:the Karanahan technology and in situ vaccination,which are based on chronometric delivery of therapeutic agents to the tumor depending on the characteristics of tumor cells,as well as the immune status.The main purpose of this study was to experimentally prove the feasibility of combining the Karanahan technology and in situ vaccination withαOX40 antibodies into a single therapeutic platform to achieve a potent additive antitumor therapeutic effect.Methods:BALB/c mice grafted with B-cellular lymphoma A20 were treated using the Karanahan technology consisting of intraperitoneal cyclophosphamide administrations and intratumoral DNA injections according to an individually determined therapeutic regimen,together with in situ vaccination withαOX40.A pathomorphological analysis of the organs of experimental animals that died during the initial attempt to combine the two technologies was carried out.An analysis of blood cell populations was performed to determine the safe time for antibody administration:the number of immune cells capable of activating systemic inflammation(CD11b+Ly-6C+,CD11b+Ly-6G+,CD3–NKp46+CD11b+),the presence of Fc receptor and OX40 on the surface of these cells,and the number of neutrophils activated to NETosis were analyzed.Based on the analysis results,the antitumor efficacy of various modes of combining the Karanahan technology and in situ vaccination was studied.Results:WhenαOX40 was administered 5 h after each treatment using the Karanahan technology,mass death of mice caused by systemic inflammation and multiple organ failure was observed.The state of blood cells after the treatment using the Karanahan technology at the time points corresponding to antibody injections was analyzed to elucidate the reasons for this effect.It was found that at some time points,there occurs activation of the immune system and a powerful release(up to 16%)of monocytes and granulocytes carrying Fc receptor and OX40 on their surface into blood;when interacting withαOX40,they can activate the lytic potential of these cells.Activation of neutrophils to NETosis was also observed.Based on these findings,a study was carried out in different time regimes to combine the Karanahan technology andαOX40 injections.WhenαOX40 was injected into the points of minimal release of myeloid cells into the blood,increased survival rate and the greatest antitumor efficacy were observed:37%of animals survived without relapses on day 100 after experiment initiation.Conclusions:The results obtained indicate that it is possible to combine the Karanahan technology and in situ vaccination withαOX40,with obligatory constant monitoring of the number of myeloid cells in peripheral blood to determine the safe time for antibody injection.展开更多
Objective:We assessed the safety and clinical effectiveness of intranasal therapy with M2 macrophage-derived soluble products(M2-SPs)for treating patients with cerebrovascular disease(CVD).Materials and methods:The pr...Objective:We assessed the safety and clinical effectiveness of intranasal therapy with M2 macrophage-derived soluble products(M2-SPs)for treating patients with cerebrovascular disease(CVD).Materials and methods:The protocol of the study was registered at www.ClinicalTrails.gov(NCT02957123).The study group comprised 30 patients with chronic CVD.Neurological status was examined before therapy and at 1-and 6-month follow–up.Concentrations of 32 cytokines in the blood serum were evaluated before and 1 month after therapy onset.Neurological assessment was conducted with the following scales:Subjective Assessment of Clinical(neurological)Symptoms(SACS),Hospital Anxiety and Depression Scale(HADS),Functional Mobility Assessment in Eldery Patients(FMA),and Montreal Cognitive Assessment(MoCa).Results:M2-SPs treatment(once daily for 28~30 days)was found to be safe and well tolerated.Neuropsychological improvements showed the amelioration of neurological symptoms,reduction in anxiety and depression levels,improvement in balance and gait ability as well as cognitive functions.Clinical effects could be detected at the end of treatment course and was stable during 6-month follow-up.Blood serum cytokine evaluation demonstrated diminished baseline levels of many cytokines including those with neurotrophic activity(brain-derived neurotrophic factor,BDNF;hepatocyte growth factor,HGF;migration inhibitory factor,MIF).Upon treatment,most pronounced clinical responses were observed in patients with most severe cytokine deficiency and post-therapy normalization of MIF and HGF levels.Conclusion:Intranasal therapy with M2-SPs is safe and according to preliminary data reduces neuropsychological deficit in patients with chronic CVD.The positive effect of M2-SPs treatment seems to be HGF-and MIF-dependent.展开更多
基金supported by Inga N.Zaitseva“Karanahan”LLC and the Ministry of Science and Higher Education of the Russian Federation via the Institute of Cytology and Genetics(State Budget Project No.FWNR-2022-0016).
文摘Objectives:Currently,there exist two approaches to the treatment of malignant neoplasms:the Karanahan technology and in situ vaccination,which are based on chronometric delivery of therapeutic agents to the tumor depending on the characteristics of tumor cells,as well as the immune status.The main purpose of this study was to experimentally prove the feasibility of combining the Karanahan technology and in situ vaccination withαOX40 antibodies into a single therapeutic platform to achieve a potent additive antitumor therapeutic effect.Methods:BALB/c mice grafted with B-cellular lymphoma A20 were treated using the Karanahan technology consisting of intraperitoneal cyclophosphamide administrations and intratumoral DNA injections according to an individually determined therapeutic regimen,together with in situ vaccination withαOX40.A pathomorphological analysis of the organs of experimental animals that died during the initial attempt to combine the two technologies was carried out.An analysis of blood cell populations was performed to determine the safe time for antibody administration:the number of immune cells capable of activating systemic inflammation(CD11b+Ly-6C+,CD11b+Ly-6G+,CD3–NKp46+CD11b+),the presence of Fc receptor and OX40 on the surface of these cells,and the number of neutrophils activated to NETosis were analyzed.Based on the analysis results,the antitumor efficacy of various modes of combining the Karanahan technology and in situ vaccination was studied.Results:WhenαOX40 was administered 5 h after each treatment using the Karanahan technology,mass death of mice caused by systemic inflammation and multiple organ failure was observed.The state of blood cells after the treatment using the Karanahan technology at the time points corresponding to antibody injections was analyzed to elucidate the reasons for this effect.It was found that at some time points,there occurs activation of the immune system and a powerful release(up to 16%)of monocytes and granulocytes carrying Fc receptor and OX40 on their surface into blood;when interacting withαOX40,they can activate the lytic potential of these cells.Activation of neutrophils to NETosis was also observed.Based on these findings,a study was carried out in different time regimes to combine the Karanahan technology andαOX40 injections.WhenαOX40 was injected into the points of minimal release of myeloid cells into the blood,increased survival rate and the greatest antitumor efficacy were observed:37%of animals survived without relapses on day 100 after experiment initiation.Conclusions:The results obtained indicate that it is possible to combine the Karanahan technology and in situ vaccination withαOX40,with obligatory constant monitoring of the number of myeloid cells in peripheral blood to determine the safe time for antibody injection.
文摘Objective:We assessed the safety and clinical effectiveness of intranasal therapy with M2 macrophage-derived soluble products(M2-SPs)for treating patients with cerebrovascular disease(CVD).Materials and methods:The protocol of the study was registered at www.ClinicalTrails.gov(NCT02957123).The study group comprised 30 patients with chronic CVD.Neurological status was examined before therapy and at 1-and 6-month follow–up.Concentrations of 32 cytokines in the blood serum were evaluated before and 1 month after therapy onset.Neurological assessment was conducted with the following scales:Subjective Assessment of Clinical(neurological)Symptoms(SACS),Hospital Anxiety and Depression Scale(HADS),Functional Mobility Assessment in Eldery Patients(FMA),and Montreal Cognitive Assessment(MoCa).Results:M2-SPs treatment(once daily for 28~30 days)was found to be safe and well tolerated.Neuropsychological improvements showed the amelioration of neurological symptoms,reduction in anxiety and depression levels,improvement in balance and gait ability as well as cognitive functions.Clinical effects could be detected at the end of treatment course and was stable during 6-month follow-up.Blood serum cytokine evaluation demonstrated diminished baseline levels of many cytokines including those with neurotrophic activity(brain-derived neurotrophic factor,BDNF;hepatocyte growth factor,HGF;migration inhibitory factor,MIF).Upon treatment,most pronounced clinical responses were observed in patients with most severe cytokine deficiency and post-therapy normalization of MIF and HGF levels.Conclusion:Intranasal therapy with M2-SPs is safe and according to preliminary data reduces neuropsychological deficit in patients with chronic CVD.The positive effect of M2-SPs treatment seems to be HGF-and MIF-dependent.
